3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
CNS
1
Conditions
Recurrence
2
Multiple Myeloma
2
Lymphoma, B-Cell
2
Burkitt Lymphoma
2
Neoplasms, Plasma Cell
1
Neoplasms
1
Meningeal Carcinomatosis
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Hodgkin Disease
1
Interventions
Pemetrexed
5
Bevacizumab
5
osimertinib
3
aflutinib
3
Temozolomide
3
trastuzumab deruxtecan
2
Topotecan
2
Spinal Puncture
2
Specimen Handling
2
Radiotherapy, Intensity-Modulated
2
Methotrexate
2
Magnetic Resonance Spectroscopy
2
tucatinib
1
trioctyl phosphine oxide
1
pembrolizumab
1
nimotuzumab
1
merphos
1
lenvatinib
1
glutathione pegylated liposomal doxorubicin
1
epothilone B
1
envafolimab
1
camrelizumab
1
XL647
1
Trastuzumab
1
Transplantation, Autologous
1
Radiotherapy
1
Radiosurgery
1
Nivolumab
1
Mental Status and Dementia Tests
1
Ipilimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Meningeal Carcinomatosis
×
Transplantation, Autologous
×
Clear all
NCT00801216
2024-12-10
SCNSL1
IRCCS San Raffaele
Phase 2
Completed
40 enrolled
11 charts